Health Care • Medicinal Chemicals and Botanical Products
$78.03 ▲ +1.28
(+1.67%)
MKT CAP: $128.15B • VOL: 20.52M
52W L $55 52W H $80
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$66
MEDIAN
$87
MEAN
$89
HIGH
$106
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MO TAPE
MO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $94.42 | $89.73 | 2025-02-14 | $71.01 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $98.32 | $92.08 | 2025-02-06 | $73.35 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $88.95 | $85.83 | 2025-01-29 | $74.91 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $79.59 | — | 2025-01-17 | $76.47 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $68.67 | $74.13 | 2025-01-09 | $69.45 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $92.86 | $81.15 | 2024-12-18 | $67.89 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $75.69 | $78.81 | 2024-12-04 | $72.57 | -4.3% | 48% | C |